SCHEDULE: Millennium Funds Disclose 8.4% Stake in BioXcel

Millennium Management and affiliated entities have reported an 8.4% beneficial ownership stake in BioXcel Therapeutics, Inc. as of December 31, 2025.

Summary

• Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have filed an Amendment No. 1 to Schedule 13G.
• The filing reports beneficial ownership of common stock in BioXcel Therapeutics, Inc. (CUSIP: 09075P204).
• As of December 31, 2025, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander each beneficially own 1,835,192 shares, representing 8.4% of the class.
• Integrated Core Strategies (US) LLC beneficially owns 1,833,717 shares, also representing 8.4% of the class.
• The reporting persons share voting and dispositive power over these shares.
• The shares were not acquired for the purpose of changing or influencing control of BioXcel Therapeutics, Inc.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a substantial investment by Millennium Management suggests a favorable view of BioXcel Therapeutics' long-term prospects, even if it's a passive stake.

Positives

• A significant stake by a prominent investment firm like Millennium Management can signal institutional confidence in BioXcel Therapeutics, Inc.
• The passive nature of the filing (Schedule 13G) indicates the investment is not intended to influence control, suggesting a belief in the company's current strategy.

Future Outlook

NA

Management Comments

• The securities disclosed herein as potentially beneficially owned by Millennium Management LLC, Millennium Group Management LLC and Mr. Englander are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC (the managing member of Millennium Management LLC) and Mr. Englander (the sole voting trustee of the managing member of Millennium Group Management LLC).
• The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities.
• By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

Industry Context

StockSavvy.ai notes that significant ownership stakes by large, sophisticated hedge funds like Millennium Management are often closely watched by the market. In the biotechnology sector, such investments can signal a belief in a company's drug pipeline, market potential, or strategic direction, especially for smaller firms like BioXcel Therapeutics.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake could instill greater confidence among existing and potential shareholders, potentially leading to increased demand for the stock.

Key Dates

Recommendation

While the disclosure of a significant stake by a reputable institutional investor like Millennium Management is generally a positive indicator, this filing alone does not provide sufficient operational or financial details to warrant a 'buy' recommendation. It primarily signals institutional confidence, suggesting existing investors should 'hold' their positions, but further analysis of BioXcel's fundamentals would be required for a stronger recommendation.

Keywords

BioXcel Therapeutics, BXCL, Millennium Management, Integrated Core Strategies, Israel A. Englander, Schedule 13G, Beneficial Ownership, Institutional Investor, Biotechnology, Pharmaceuticals